Hospital
Sanford Medical Center Fargo
Sanford Medical Center Fargo was paid $50.18M by Medicaid between Jan 2018 and Dec 2024, across 302 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 32% of everything it billed.
33Billing provider infoSANFORD MEDICAL CENTER FARGO
FARGO, ND 58122
FARGO, ND 58122
33aNPI1528009412assigned 06/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$50.18M
24GClaims680,370
24DCodes billed302
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Dakota
Rank by total paid#1 of 8
Median peer was paid$750K
This provider vs. median67×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORRISON, TONY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 132,501 | $4.89M | |
| 2019 | 92,499 | $7.01M | |
| 2020 | 72,724 | $5.83M | |
| 2021 | 110,450 | $8.85M | |
| 2022 | 103,437 | $9.00M | |
| 2023 | 100,261 | $8.72M | |
| 2024incomplete | 68,498 | $5.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 32% | 238,370 | 213,492 | $16.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 37,844 | 35,227 | $12.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 32,181 | 30,443 | $5.32M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.3% | 18,615 | 17,590 | $4.68M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 4.3% | 7,155 | 3,572 | $2.17M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 20,696 | 19,009 | $918K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 3,339 | 2,983 | $768K |
| 62323 | 1.3% | 1,180 | 1,076 | $635K | |
| 64615 | 1.2% | 3,519 | 3,286 | $621K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 910 | 820 | $558K |
| 36415 | Collection of venous blood by venipuncture | <1% | 40,692 | 36,059 | $485K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,094 | 1,250 | $401K |
290 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,408 | $320K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,149 | $265K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,363 | $240K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 4,241 | $240K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 240 | $194K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 1,106 | $174K |
| 97597 | <1% | 1,952 | $142K | |
| 80053 | Comprehensive metabolic panel | <1% | 43,426 | $133K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,325 | $129K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,467 | $128K |
| 93325 | <1% | 2,601 | $124K | |
| G0378 | Hospital observation service, per hour | <1% | 503 | $116K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 102 | $112K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,674 | $107K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 232 | $104K |
| 93304 | <1% | 428 | $102K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,160 | $99K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 134 | $98K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,569 | $91K |
| 90870 | <1% | 181 | $83K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,230 | $81K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 914 | $77K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 731 | $71K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,821 | $71K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 312 | $63K |
| 93321 | <1% | 544 | $49K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 160 | $49K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,848 | $46K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 80 | $46K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 124 | $43K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,539 | $42K |
| 59025 | Fetal non-stress test | <1% | 498 | $42K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,947 | $41K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,875 | $40K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 48,723 | $39K |
| 93296 | <1% | 2,180 | $39K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 175 | $38K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 395 | $37K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 283 | $33K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 80 | $33K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 106 | $32K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 24 | $31K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 377 | $28K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 143 | $28K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 915 | $28K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 194 | $28K |
| 90686 | <1% | 4,031 | $28K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,492 | $26K |
| 64643 | <1% | 112 | $24K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,571 | $22K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 304 | $21K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 273 | $21K |
| 64642 | <1% | 114 | $18K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 70 | $18K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 246 | $18K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 395 | $18K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 20 | $17K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 76 | $16K |
| 11721 | <1% | 1,681 | $16K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 187 | $16K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 175 | $15K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 129 | $15K |
| 0002A | <1% | 491 | $15K | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 15 | $15K |
| 0001A | <1% | 461 | $14K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 625 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 90 | $13K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,803 | $12K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 238 | $12K |
| 49083 | <1% | 20 | $12K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 72 | $12K |
| 97165 | <1% | 180 | $12K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 83 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 298 | $11K |
| 95886 | <1% | 108 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 751 | $11K |
| 97161 | <1% | 318 | $10K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 3,073 | $10K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 410 | $10K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 185 | $9K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 93 | $9K |
| 0240U | <1% | 68 | $9K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 73 | $8K |
| J3490 | Unclassified drugs | <1% | 1,622 | $8K |
| 93299 | <1% | 398 | $8K | |
| 73630 | <1% | 303 | $8K | |
| 95117 | <1% | 261 | $8K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 28 | $8K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 34 | $7K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 46 | $7K |
| 98940 | <1% | 301 | $7K | |
| 93320 | <1% | 136 | $7K | |
| 92134 | <1% | 2,325 | $7K | |
| 92526 | <1% | 173 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 128 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,129 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 39 | $6K |
| 76000 | <1% | 127 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,970 | $6K |
| 76770 | <1% | 80 | $6K | |
| 97162 | <1% | 144 | $6K | |
| 73610 | <1% | 119 | $6K | |
| 92523 | <1% | 57 | $6K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 73 | $5K |
| 82077 | <1% | 2,612 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 50 | $5K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 13 | $4K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 29 | $4K |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 3,726 | $4K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 189 | $4K |
| 96367 | <1% | 165 | $4K | |
| 80061 | Lipid panel | <1% | 757 | $4K |
| 64644 | <1% | 14 | $4K | |
| 20610 | <1% | 178 | $3K | |
| 84484 | <1% | 3,448 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 617 | $3K |
| 97810 | <1% | 106 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 87 | $3K |
| 71250 | <1% | 82 | $3K | |
| 93298 | <1% | 106 | $3K | |
| 92567 | <1% | 183 | $3K | |
| 90662 | <1% | 107 | $3K | |
| 20611 | <1% | 24 | $3K | |
| 17250 | <1% | 44 | $3K | |
| 90656 | <1% | 249 | $3K | |
| 17110 | <1% | 14 | $3K | |
| 73562 | <1% | 251 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 363 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,857 | $3K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 14 | $2K |
| 94060 | <1% | 12 | $2K | |
| 97166 | <1% | 41 | $2K | |
| 86140 | <1% | 1,862 | $2K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 13 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 236 | $2K |
| 0072A | <1% | 61 | $2K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 282 | $2K |
| 83690 | <1% | 4,000 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 210 | $2K |
| 90480 | <1% | 100 | $2K | |
| 73130 | <1% | 29 | $2K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 361 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,983 | $2K |
| 93226 | <1% | 27 | $2K | |
| 87210 | <1% | 51 | $2K | |
| 88304 | <1% | 93 | $2K | |
| 51798 | <1% | 57 | $2K | |
| 99173 | <1% | 27 | $2K | |
| 81001 | <1% | 3,363 | $1K | |
| 86780 | <1% | 97 | $1K | |
| 0054A | <1% | 65 | $1K | |
| 0071A | <1% | 42 | $1K | |
| V2632 | Posterior chamber intraocular lens | <1% | 508 | $1K |
| 82805 | <1% | 354 | $1K | |
| 93971 | <1% | 30 | $1K | |
| 90717 | <1% | 13 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,869 | $1K |
| 96116 | <1% | 16 | $1K | |
| 84702 | <1% | 1,446 | $1K | |
| 97602 | <1% | 21 | $1K | |
| 73110 | <1% | 45 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 38 | $1K |
| 83735 | <1% | 2,566 | $1K | |
| 97116 | <1% | 71 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,081 | $1K |
| 96415 | <1% | 14 | $1K | |
| 0124A | <1% | 43 | $1K | |
| 87631 | <1% | 197 | $1K | |
| 0004A | <1% | 47 | $983.97 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,501 | $975.32 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,944 | $966.97 |
| 85027 | <1% | 3,006 | $954.84 | |
| 99188 | <1% | 594 | $945.43 | |
| 83605 | <1% | 910 | $864.73 | |
| 0052A | <1% | 25 | $845.17 | |
| 92611 | <1% | 14 | $840.88 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 17 | $732.00 |
| 95874 | <1% | 62 | $717.54 | |
| 86850 | <1% | 147 | $649.14 | |
| 99411 | <1% | 14 | $581.84 | |
| 95115 | <1% | 22 | $572.35 | |
| G0008 | Administration of influenza virus vaccine | <1% | 136 | $563.68 |
| 91320 | <1% | 13 | $560.79 | |
| 0051A | <1% | 17 | $560.48 | |
| 83880 | <1% | 211 | $552.50 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 324 | $552.27 |
| 84703 | <1% | 1,026 | $530.71 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 296 | $530.40 |
| 77003 | <1% | 62 | $505.50 | |
| 86803 | <1% | 39 | $504.52 | |
| 74230 | <1% | 14 | $499.80 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 50 | $499.69 |
| D0140 | Limited oral evaluation - problem focused | <1% | 25 | $468.73 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 297 | $444.17 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 150 | $399.40 |
| 88342 | <1% | 17 | $367.15 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,103 | $360.70 |
| 94664 | <1% | 358 | $356.67 | |
| 92136 | <1% | 43 | $338.67 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $337.08 |
| 86900 | <1% | 163 | $325.17 | |
| 94729 | <1% | 27 | $315.42 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15 | $305.88 |
| 97035 | <1% | 54 | $280.91 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 201 | $272.38 |
| 81025 | <1% | 139 | $265.64 | |
| 73564 | <1% | 13 | $258.39 | |
| 73030 | <1% | 46 | $250.70 | |
| 92133 | <1% | 56 | $249.58 | |
| 82784 | <1% | 26 | $238.50 | |
| 85652 | <1% | 355 | $210.05 | |
| 36416 | <1% | 126 | $201.50 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,089 | $200.07 |
| 90691 | <1% | 12 | $188.28 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $179.08 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $179.08 |
| 83550 | <1% | 53 | $177.35 | |
| 85610 | <1% | 983 | $175.66 | |
| 86901 | <1% | 162 | $174.50 | |
| 84439 | <1% | 25 | $162.87 | |
| 82570 | <1% | 133 | $155.52 | |
| 83540 | <1% | 40 | $150.23 | |
| 72100 | <1% | 29 | $144.30 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 28 | $139.12 |
| 91305 | <1% | 15 | $127.15 | |
| 94010 | <1% | 45 | $124.36 | |
| 91300 | <1% | 128 | $118.38 | |
| 80050 | General health panel | <1% | 30 | $100.16 |
| 82728 | <1% | 70 | $96.19 | |
| 83615 | <1% | 175 | $92.72 | |
| 74018 | <1% | 63 | $91.01 | |
| 80197 | <1% | 21 | $85.15 | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 54 | $78.83 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 546 | $78.53 |
| 96376 | <1% | 457 | $76.39 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 18 | $76.30 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 15 | $66.15 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 174 | $57.68 |
| 81003 | <1% | 619 | $47.56 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 246 | $27.75 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 160 | $16.68 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 161 | $5.76 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 42 | $0.64 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,779 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 219 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 62 | $0.00 |
| 80179 | 0% | 61 | $0.00 | |
| 80143 | 0% | 79 | $0.00 | |
| 82565 | 0% | 101 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 143 | $0.00 |
| 87186 | 0% | 146 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 173 | $0.00 |
| 85014 | 0% | 28 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 67 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 37 | $0.00 |
| 80076 | 0% | 31 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 24 | $0.00 |
| 90715 | 0% | 12 | $0.00 | |
| 84100 | 0% | 13 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 58 | $0.00 |
| 84156 | 0% | 18 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 110 | $0.00 |
| C1769 | Guide wire | 0% | 343 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 217 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 260 | $0.00 |
| 85379 | 0% | 104 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 76 | $0.00 |
| 82607 | 0% | 42 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 15 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 133 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 43 | $0.00 |
| 85018 | 0% | 158 | $0.00 | |
| 87077 | 0% | 164 | $0.00 | |
| 73502 | 0% | 41 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 46 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,814 | $0.00 |
| 87070 | 0% | 94 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 38 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 44 | $0.00 |
| 85730 | 0% | 59 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 68 | $0.00 |
| 87040 | 0% | 153 | $0.00 | |
| 80069 | 0% | 224 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 61 | $0.00 |
| 87205 | 0% | 15 | $0.00 | |
| 80047 | 0% | 25 | $0.00 | |
| 84132 | 0% | 28 | $0.00 | |
| 82550 | 0% | 54 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 28 | $0.00 |
| 82043 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORRISON, TONY (VICE PRESIDENT, REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Sanford Health of Northern Minnesota | Bemidji, MN | $47.45M |
| Sanford Bismarck | Bismarck, ND | $43.96M |
| Sanford Health of Northern Minnesota | Bemidji, MN | $27.11M |
| Sanford Medical Center | Sioux Falls, SD | $24.40M |
| FM Ambulance Service, INC | Fargo, ND | $23.80M |
| Sanford Medical Center | Sioux Falls, SD | $18.03M |
| Sanford Health Network | Worthington, MN | $7.58M |
| Sanford Clinic | Sioux Falls, SD | $6.04M |
| Sanford Clinic | Sioux Falls, SD | $5.45M |
| Sanford Healthcare Accessories, LLC | Fargo, ND | $4.79M |
| Sanford Health Network North | Thief River Falls, MN | $3.28M |
| Sanford Clinic | Sioux Falls, SD | $2.96M |
| Sanford Health Network | Jackson, MN | $2.81M |
| Sanford Clinic | Watertown, SD | $2.02M |
| Black Hills Orthopedic & Spine Center, INC. | Rapid City, SD | $1.71M |
| Sanford Health Network | Chamberlain, SD | $1.47M |
| Sanford Health Network | Vermillion, SD | $1.31M |
| Sanford Health Network | Luverne, MN | $1.27M |
| Sanford Medical Center Fargo | Pelican Rapids, MN | $1.01M |
| Sanford Medical Center Fargo | Mahnomen, MN | $994K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.